Previous studies have shown that the MET exon 14 skipping mutation occurred in approximately 3–5% of lung adenocarcinoma cases, slightly more than 2% of squamous cell carcinomas, and 2.3% of other lung cancer histology types (6, 28, 29). This evidence concerns the gene MET and lung adenocarcinoma.